Mercury in aquatic ecosystems of two indigenous communities in the Piedmont Ecuadorian Amazon: evidence from fish, water, and sediments.

Mercury is a highly toxic element present in water, soil, air, and biota. Anthropogenic activities, such as burning fossil fuels, mining, and deforestation, contribute to the presence and mobilization of mercury between environmental compartments. Although current research on mercury pathways has advanced our understanding of the risks associated with human exposure, limited information exists for remote areas with high diversity of fauna, flora, and indigenous communities. This study aims to deepen our understanding of the presence of total mercury in water, sediments, and fish, within aquatic ecosystems of two indigenous territories: Gomataon (Waorani Nationality) and Sinangoé (Ai´Cofán Nationality) in the Ecuadorian Amazon. Our findings indicate that, for most fish (91.5%), sediment (100%) and water (95.3%) samples, mercury levels fall under international limits. For fish, no significant differences in mercury levels were detected between the two communities. However, eight species exceeded recommended global limits, and one surpassed the threshold according to Ecuadorian legislation. Piscivore and omnivore fish exhibited the highest concentrations of total mercury among trophic guilds. Only one water sample from each community's territory exceeded these limits. Total mercury in sediments exhibited greater concentrations in Gomataon than Sinangoé. Greater levels of mercury in sediments were associated with the occurrence of total organic carbon. Considering that members of the communities consume the analyzed fish, an interdisciplinary approach, including isotopic analysis, methylmercury sampling in humans, and mercury monitoring over time, is imperative for a detailed risk assessment of mercury exposure in Amazonian communities.

The incidence of unfilled second mesiobuccal canals and periapical lesions in maxillary molars by cone-beam computed tomography E-VOL DX software

This study evaluated the incidence of unfilled second mesiobuccal (MB2) canals and periapical lesions in first maxillary molars using CBCT e-Vol DX software. Hence, 326 CBCT images of first maxillary molars of patients undergoing endodontic treatment were selected. The e-Vol DX software performed a retrospective review of these images, recording the presence or absence of MB2 canals, filling, and periapical lesions in first maxillary molars. Specific statistical analysis was performed at a 5% significance level. Unfilled MB2 canals were highly frequent in first maxillary molars and significantly associated with periapical lesions in the mesiobuccal root of these teeth (p<0.05). The CBCT e-Vol DX software effectively detected MB2 canals, and unfilled canals may be associated with periapical lesions.

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.

INTRODUCTION: The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses. METHODS: RHH-001 is a phase 4, participant masked, two centre, safety and immunogenicity study of Brazilian adults (18 years and older) in São Paulo or Salvador who had received two doses of CoronaVac 6 months previously. The third heterologous dose was of either a recombinant adenoviral vectored vaccine (Ad26.COV2-S, Janssen), an mRNA vaccine (BNT162b2, Pfizer-BioNTech), or a recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca), compared with a third homologous dose of CoronaVac. Participants were randomly assigned (5:6:5:5) by a RedCAP computer randomisation system stratified by site, age group (18-60 years or 61 years and over), and day of randomisation, with a block size of 42. The primary outcome was non-inferiority of anti-spike IgG antibodies 28 days after the booster dose in the heterologous boost groups compared with homologous regimen, using a non-inferiority margin for the geometric mean ratio (heterologous vs homologous) of 0·67. Secondary outcomes included neutralising antibody titres at day 28, local and systemic reactogenicity profiles, adverse events, and serious adverse events. This study was registered with Registro Brasileiro de Ensaios Clínicos, number RBR-9nn3scw. FINDINGS: Between Aug 16, and Sept 1, 2021, 1240 participants were randomly assigned to one of the four groups, of whom 1239 were vaccinated and 1205 were eligible for inclusion in the primary analysis. Antibody concentrations were low before administration of a booster dose with detectable neutralising antibodies of 20·4% (95% CI 12·8-30·1) in adults aged 18-60 years and 8·9% (4·2-16·2) in adults 61 years or older. From baseline to day 28 after the booster vaccine, all groups had a substantial rise in IgG antibody concentrations: the geometric fold-rise was 77 (95% CI 67-88) for Ad26.COV2-S, 152 (134-173) for BNT162b2, 90 (77-104) for ChAdOx1 nCoV-19, and 12 (11-14) for CoronaVac. All heterologous regimens had anti-spike IgG responses at day 28 that were superior to homologous booster responses: geometric mean ratios (heterologous vs homologous) were 6·7 (95% CI 5·8-7·7) for Ad26.COV2-S, 13·4 (11·6-15·3) for BNT162b2, and 7·0 (6·1-8·1) for ChAdOx1 nCoV-19. All heterologous boost regimens induced high concentrations of pseudovirus neutralising antibodies. At day 28, all groups except for the homologous boost in the older adults reached 100% seropositivity: geometric mean ratios (heterologous vs homologous) were 8·7 (95% CI 5·9-12·9) for Ad26.COV2-S vaccine, 21·5 (14·5-31·9) for BNT162b2, and 10·6 (7·2-15·6) for ChAdOx1 nCoV-19. Live virus neutralising antibodies were also boosted against delta (B.1.617.2) and omicron variants (B.1.1.529). There were five serious adverse events. Three of which were considered possibly related to the vaccine received: one in the BNT162b2 group and two in the Ad26.COV2-S group. All participants recovered and were discharged home. INTERPRETATION: Antibody concentrations were low at 6 months after previous immunisation with two doses of CoronaVac. However, all four vaccines administered as a third dose induced a significant increase in binding and neutralising antibodies, which could improve protection against infection. Heterologous boosting resulted in more robust immune responses than homologous boosting and might enhance protection. FUNDING: Ministry of Health, Brazil.

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.

Angiotensin-converting enzyme-2 (ACE2) expression may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain. DESIGN: BRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 34 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from cardiovascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, and troponin, B-type natriuretic peptide (BNP), N-terminal-proBNP, and D-dimer levels. SUMMARY: BRACE CORONA will evaluate whether the strategy of continued ACEI/ARB therapy compared with temporary discontinuation of these drugs impacts clinical outcomes among patients with COVID-19.

Índice Manchester de incapacidade associada ao pé doloroso no idoso: tradução, adaptação cultural e validação para a língua portuguesa / Manchester foot pain associated disability index in the feet of elderly people: cultural adaptation, validation, and translation into the portuguese language

OBJETIVO: O objetivo do estudo foi realizar a tradução e a adaptação e estudar as propriedades das medidas: reprodutibilidade, validade e consistência interna do índice Manchester de incapacidade associada ao pé doloroso no idoso (MFPDI) para a língua portuguesa. MÉTODOS: O MFPDI foi traduzido e adaptado culturalmente para uma população de idosos, residentes na cidade de São Paulo. Foram avaliados 85 pacientes ambulatoriais com idade de 60 anos ou mais, de ambos os sexos, que apresentavam dor nos pés de 30 mm ou mais na escala analógica visual de dor (EVA). Os pacientes foram submetidos ao MFPDI por três vezes, visto que na primeira vez cada paciente foi avaliado pelos entrevistadores 1 e 2 no mesmo dia, e no período máximo de 15 dias cada paciente foi, novamente, avaliado pelo entrevistador 1 para realizar a fase de reprodutibilidade. Para verificar a validade, foram colhidas medidas sociodemográficas, morfológicas e valores da escala analógica visual. E para a consistência interna foi aplicado o alfa de Cronbach, a fim de verificar a confiabilidade das respostas nas três entrevistas. RESULTADOS: Ao utilizar o processo metodológico, foi possível observar que a população ambulatorial entrevistada apresentou incapacidade funcional associada ao pé doloroso. A consistência interna foi alta (alfa de Cronbach = 0,80) entre as entrevistas. A validade foi obtida comparando-se o MFPDI com a EVA, sendo possível observar que, apesar de baixa, a correlação foi significante (p < 0,001). CONLUSÃO: Com o processo de tradução e adaptação cultural do MFPDI demonstraram-se as propriedades de medida de reprodutibilidade, validade e consistência interna.

OBJECTIVE: This work aimed to translate into Portuguese, make adaptations, and study the reproducibility, validation and internal consistency of the parameters of the "Manchester Foot-Pain Disability Index". METHODS: The MFPDI was translated and culturally adapted in a population of eighty-five (85) elderly people, living in the city of São Paulo, seen at the outpatient clinics of the .Instituto de Geriatria e Gerontologia of the Escola Paulista de Medicina. The patients had at least 60 years-old, of either sex, displaying foot pain of at least 30 mm on a visual analog scale (VAS). Patients were evaluated by 3 times by the MFPDI, in such a way that on the first time each patient was evaluated by the interviewers 1 and 2 at the same day; to assess reproducibility, within the next 15 days each patient was evaluated again by the interviewer 1. Validation was verified by checking for social and demographic data, as well as morphological and VAS values. Internal consistency was checked by means of the Cronbach alpha, assessing reproducibility of the answers in the three interviews. RESULTS: The MFPDI index demonstrated that this population presented functional inability associated to foot pain. The internal consistency between interviews was high (Alpha of Cronbach = 0.80). Though presenting a weak correlation, there was a significant validity comparing MFPDI and the VAS (p < 0.001). CONCLUSION: The translation and cultural adaptation of the MFPDI provide a reproducible, consistent and valuable tool to evaluate foot pain.